Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Paige M GlumacJoseph P GallantMariya ShapovalovaYingming LiPaari MuruganShilpa GuptaIlsa M ColemanPeter S NelsonScott M DehmAaron M LeBeauPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
To our knowledge, this is the first study to define CD133 as a targetable marker of AVPC. Similarly, we have developed a novel imaging agent, which is selective for CD133-expressing tumors, resulting in a noninvasive PET imaging approach to more effectively detect and monitor AVPC.